Ricky Henderson, MD
Cardiovascular Disease · Anderson, SCNPI 1487667523
Payments from drug & device makers
Across 895 payments — averaging $106.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$41K
- Medtronic$30K
- Biotronik Inc.$11K
- Abbott$5K
- Biosense Webster, Inc.$3K
- Medical Device Business Services, Inc.$771
- plus $5K from 27 others
What the payments were for
- Consulting fees$15,31429%
- Speaking & faculty fees$5,10010%
- Travel & lodging$11,04921%
- Food & beverage$20,63940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 212 | $41,366 |
| Medtronic(2 entities) | 164 | $29,566 |
| Biotronik Inc. | 63 | $11,143 |
| Abbott | 191 | $5,076 |
| Biosense Webster, Inc. | 57 | $3,108 |
| Medical Device Business Services, Inc. | 4 | $771 |
| Atricure, Inc. | 14 | $718 |
| Johnson & Johnson | 26 | $473 |
| Philips North America LLC | 13 | $411 |
| E.r. Squibb & Sons, L.L.C. | 24 | $343 |
| Cardiva Medical, Inc. | 16 | $314 |
| Cvrx, Inc. | 9 | $287 |
| Elutia, Inc. | 13 | $248 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $222 |
| Pfizer | 12 | $202 |
| Edwards Lifesciences | 7 | $171 |
| Lundbeck LLC | 8 | $165 |
| Inari Medical, Inc. | 1 | $141 |
| Novartis | 7 | $122 |
| Impulse Dynamics (USA) Inc. | 5 | $85 |
| Sanofi-aventis U.S. LLC | 6 | $84 |
| Cordis US CORP. | 4 | $74 |
| BD | 3 | $73 |
| Amgen | 3 | $62 |
| Abiomed | 3 | $62 |
| Boehringer Ingelheim | 4 | $56 |
| Merck | 3 | $55 |
| Angiodynamics, Inc. | 1 | $42 |
| Kestra Medical Technology Services, Inc. | 2 | $39 |
| Altathera Pharmaceuticals LLC | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Davol Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3 System$2,633
- WATCHMAN FLX$2,448
- Arctic Front$1,826
- Reveal LINQ$1,716
- AVEIR$1,411
- SPHERE-9$1,292
- INGEVITY$929
- NA$839
- AFFERA MAPPING SYSTEM$578
- GENERAL - THERAPIES$397
- Carto 3$394
- Plexa$394
- Acticor$394
- Rivacor$394
- Edora$394
- Sentus$394
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$327
- Ensite Cardiac Mapping System$302
- WATCHMAN Access System$294
- Micra$281
How this compares
$95,558 in reported general payments places this provider in the 90th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 306 | $291,988 |
| Droxidopa | 49 | $169,020 |
| MultaqDronedarone Hcl | 24 | $42,245 |
| XareltoRivaroxaban | 48 | $37,228 |
| EntrestoSacubitril/Valsartan | 40 | $36,715 |
| Dofetilide | 114 | $27,755 |
| Ranolazine ErRanolazine | 73 | $7,962 |
| Flecainide Acetate | 84 | $4,012 |
| Mexiletine Hcl | 29 | $3,017 |
| ClopidogrelClopidogrel Bisulfate | 359 | $2,793 |
| Midodrine Hcl | 21 | $2,117 |
| Propafenone Hcl ErPropafenone Hcl | 19 | $1,671 |
| Propafenone Hcl | 32 | $1,511 |
| Fludrocortisone Acetate | 38 | $1,413 |
| Metoprolol Succinate | 128 | $1,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $202 | $291,988306 claims |
| Sanofi-aventis U.S. LLCMultaq | $84 | $42,24524 claims |
| Johnson & JohnsonXarelto | $473 | $37,22848 claims |
| NovartisEntresto | $122 | $36,71540 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Anderson
- Brent McLaurinAnderson$1.1M
- John MeehanAnderson$39K
- John WendtAnderson$12K
- Robert BiedermanCharleston$801K
- James MerriamGreenville$728K
- Vipul ShahLancaster$488K
- Arthur EberlyGreenville$438K
- Gregory SanGreenville$429K
- Naresh MoriRock Hill$408K
- Priya KumarGreenwood$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.